<?xml version="1.0" encoding="UTF-8"?>
<fig id="f6-1030717" position="float">
 <label>Figure 6.</label>
 <caption>
  <p>GvHD and transplant outcomes in patients treated with tocilizumab 
   <italic>versus</italic> a matched CIBMTR control population. (A). Cumulative incidence of grades II-IV aGvHD in patients treated with tocilizumab 
   <italic>versus</italic> the matched control cohort. (B). Probability of grades II-IV aGvHD-free survival. (C). Cumulative incidence of cGvHD, (D) transplant-related mortality, and (E) relapse. (F) Probability of disease-free survival in patients treated with tocilizumab 
   <italic>versus</italic> the matched control cohort. Toc: tocilizumab: Tac: tacrolimus; MTX: methotrexate.
  </p>
 </caption>
 <graphic xlink:href="103717.fig6" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
